💊
Loqtorzi
toripalimab
Carcinoma Nasofaríngeo; Carcinoma de Células Escamosas do Esôfago
✅ Autorizado
✅
Nenhum alerta ativo
Este medicamento não apresenta escassez contínua, cartas de segurança ou recolhimentos.
Para que serve
Loqtorzi, in combination with cisplatin and gemcitabine, is indicated for the first-line treatment of adult patients with recurrent, not amenable to surgery or radiotherapy, or metastatic nasopharyngeal carcinoma. Loqtorzi, in combination with cisplatin and paclitaxel, is indicated for the first-line treatment of adult patients with unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma.
⚠️ Segurança do paciente
No
Página oficial da EMA
https://www.ema.europa.eu/en/medicines/human/EPAR/loqtorzi